Holen Sie sich die Stockscreener-App
66.31
0.47%
-0.51
Schlusskurs vom Vortag:
$66.82
Offen:
$66.35
24-Stunden-Volumen:
289.63K
Relative Volume:
0.10
Marktkapitalisierung:
$14.79B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$556.70M
KGV:
27.98
EPS:
2.37
Netto-Cashflow:
$970.10M
1W Leistung:
+0.01%
1M Leistung:
+1.80%
6M Leistung:
-7.81%
1J Leistung:
-20.06%
1-Tages-Spanne:
$65.35
$67.01
1-Wochen-Bereich:
$64.78
$67.52
52-Wochen-Spanne:
$51.90
$84.67
Hologic Inc Stock (HOLX) Company Profile
Firmenname
Hologic Inc
Sektor
Telefon
(508) 263-2900
Adresse
250 CAMPUS DRIVE, MARLBOROUGH, MA
Vergleichen Sie HOLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
66.35 | 14.48B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
476.25 | 179.42B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
175.09 | 52.03B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
86.33 | 44.11B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
273.69 | 40.68B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
236.40 | 17.92B | 2.90B | 467.20M | 306.90M | 6.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-27 | Bestätigt | Needham | Hold |
| 2025-03-03 | Herabstufung | Argus | Buy → Hold |
| 2025-02-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | Herabstufung | Needham | Buy → Hold |
| 2024-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-12-10 | Bestätigt | Needham | Buy |
| 2024-10-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-27 | Eingeleitet | Stephens | Overweight |
| 2024-04-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-14 | Hochstufung | Needham | Hold → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-07-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-07-20 | Eingeleitet | UBS | Neutral |
| 2022-07-18 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-11-20 | Herabstufung | Needham | Buy → Hold |
| 2020-11-05 | Bestätigt | Needham | Buy |
| 2020-06-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-06-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | Bestätigt | Needham | Buy |
| 2020-04-30 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-01-31 | Bestätigt | Needham | Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-09-13 | Herabstufung | BofA/Merrill | Buy → Neutral |
Alle ansehen
Hologic Inc Aktie (HOLX) Neueste Nachrichten
Stock Analysis | Hologic OutlookA Closer Look at Mixed Signals and Market Trends - AInvest
Hologic 2025 Q3 Earnings Beats Expectations as Net Income Grows 0.2% - AInvest
Hologic, Inc. shares fall 1.53% after-hours following Morgan Stanley's price target adjustment to $69. - AInvest
Mizuho raises Hologic stock price target to $75 on strong quarterly results - Investing.com Canada
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down - Yahoo Finance
Hologic revenue increases 1.2% to USD 1,023.8M in Q2 2025 - Medical Buyer
HOLOGIC INC SEC 10-Q Report - TradingView
Hologic Inc (HOLX) Q3 2025 Earnings Call Highlights: Surpassing Expectations Amidst Challenges By GuruFocus - Investing.com Canada
Hologic (HOLX) Q3 Revenue Beats 1% - The Globe and Mail
Hologic Inc (HOLX) Q3 2025 Earnings Call Highlights: Surpassing Expectations Amidst Challenges - Yahoo.co
What markets is Hologic Inc. expanding into Is KMDA stock a good long term investment optionAdvanced Screener Ideas For Fast Growth - jammulinksnews.com
Hologic Announces Financial Results for Third Quarter of Fiscal 2025 - BioSpace
Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance - TipRanks
Hologic Inc Q3 Profit Increases, Beats Estimates - Nasdaq
Hologic targets mid-single-digit organic revenue growth in 2026 as Breast Health rebounds and tariff mitigation advances - MSN
Hologic's Q3 Earnings Beat: A Strategic Turnaround in the Making? - AInvest
Hologic, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:HOLX) - Seeking Alpha
Hologic raises annual profit forecast on diagnostic and surgical demand - 1470 & 100.3 WMBD
Earnings call transcript: Hologic Q3 2025 beats earnings estimates, stock dips By Investing.com - Investing.com Nigeria
Earnings call transcript: Hologic Q3 2025 beats earnings estimates, stock dips - Investing.com Australia
Hologic Q3 2025 Earnings Call Transcript - MarketBeat
Hologic's Strategic Shift: Capitalizing on Breast Health and Surgical Growth Amid Diagnostics Downturn - AInvest
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Hologic Q2 Revenue Beats Estimates, Stock Surges - AInvest
Hologic: Fiscal Q3 Earnings Snapshot - NewsTimes
Hologic Inc (HOLX) Q3 Earnings: Non-GAAP EPS of $1.08 Beats Estimates, Revenue Surpasses $1.02 Billion - GuruFocus
Hologic Q3 2025 slides: modest growth amid mixed segment performance By Investing.com - Investing.com South Africa
Hologic Q3 2025 slides: modest growth amid mixed segment performance - Investing.com Australia
Hologic earnings beat by $0.03, revenue topped estimates - Investing.com Australia
Hologic shares jump 7% as Q3 earnings and guidance top expectations - Investing.com India
Hologic Reports Q3 Earnings: EPS Beats Expectations, Revenue Tops Estimates - AInvest
Hologic’s (NASDAQ:HOLX) Q2 Sales Beat Estimates, Stock Soars - TradingView
Breast Biopsy Marker Market Set to Hit US$ 1.4 Billion by 2032 | Key - openPR.com
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver? - MSN
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
Does Hologic’s (HOLX) Debt Refinancing Signal a Shift in Financial Strategy? - simplywall.st
What makes Hologic Inc. stock price move sharplyProfit Focused Stock Screener Results Released - beatles.ru
Gynecological Devices Market Set to Witness Significant Growth - openPR.com
Cancer Biopsy Market Set to Witness Significant Growth - openPR.com
Short Term Charts Align With Long Term Uptrend in Hologic Inc.Smart Trade Plans With Risk Protection Explained - metal.it
Hologic Inc. Quarterly Earnings Preview: Flat Revenue and Analyst ExpectationsNews and Statistics - IndexBox
Herpes Markers Testing Market Outlook 2024 to 2034: Growth - openPR.com
Human Papilloma Virus Testing Market Research Report - GlobeNewswire
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Hologic Inc. stock outperforms competitors despite losses on the day - MarketWatch
Is it the right time to buy Hologic Inc. stockSmart Portfolio Growth Plan That Work - jammulinksnews.com
Problems With BioZorb Tissue Markers Not Adequately Disclosed by Manufacturer: Lawsuit - AboutLawsuits.com
What are the technical indicators suggesting about Hologic Inc.Exceptional earning trajectories - jammulinksnews.com
Does Hologic Inc. stock perform well during market downturnsFree Capital Allocation Plans - jammulinksnews.com
Is Hologic Inc. a growth stock or a value stockGame-changing returns - jammulinksnews.com
Finanzdaten der Hologic Inc-Aktie (HOLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):